EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co‐Inhibition of TGF ‐β and GSK ‐3 Signalling

Xiang-Jie Zhu, Zhi Zhong, Jiang-Chuan Du, Jiu-Yu Zhang, Xu Zhang, Xiu-Liang Cui, Ling-Ting Guan, Yan-Yu Hu, Can Chen, Han Wang iD, Xiang-Yu Wu, Wei-Jia Zhang und 2 weitere

Liver International · 2025

DOI: 10.1111/liv.70187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Xiang-Jie Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Metabolism & Integrative Biology, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Transforming Growth Factor beta, Benzamides, Liver Cirrhosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality, National Natural Science Foundation of China, National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Liver fibrosis, a progressive condition driven by chronic liver injury and excessive scar tissue formation, can lead to cirrhosis, a life‐threatening disease. Activation of hepatic stellate cells (HSCs) is central to fibrosis progression, yet current therapies fail to halt or reverse this process. This study evaluated a combination therapy targeting HSCs to ameliorate fibrosis and promote liver repair.

Methods

A small molecule cocktail, SBCH (SB431542, a TGF‐β inhibitor, and CHIR99021, a GSK‐3 inhibitor), was tested in three fibrosis models: CCl 4 ‐induced, bile duct ligation (BDL) and non‐alcoholic steatohepatitis (NASH) with diethylnitrosamine (DEN). Therapeutic effects were assessed using phenotypic analyses, in vivo tracing and single‐cell RNA sequencing to uncover mechanisms.

Results

SBCH significantly reduced fibrosis in all models by inhibiting HSC activation and fibrogenic activity. The suppression of PI3K/Akt pathway and EMT cascade contribute to the fibrosis‐ameliorating effect of SBCH treatment. Furthermore, in vivo tracing and single‐cell RNA sequencing revealed that SBCH induced the conversion of activated HSCs into hepatocyte‐like cells (ciHeps), which integrated into liver tissue, repaired liver damage and restored liver integrity and function.

Conclusions

SBCH mitigates liver fibrosis through multifaceted mechanisms, including the inhibition of HSC activation, suppression of fibrogenic activity and regulation of key signalling pathways such as PI3K/Akt and EMT. In addition, SBCH induces the trans‐differentiation of activated HSCs into hepatocyte‐like cells (ciHeps), effectively reducing pathogenic HSCs while increasing functional ciHeps. This dual‐target approach not only facilitates liver tissue repair but also restores liver function, offering a promising therapeutic strategy for liver fibrosis and cirrhosis, with potential applications in conditions arising from various aetiologies of liver injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsTransforming Growth Factor betaBenzamidesLiver CirrhosisDioxolesPyridinesPyrimidinesGlycogen Synthase Kinase 3AnimalsSignal TransductionMaleMiceNon-alcoholic Fatty Liver DiseaseMice, Inbred C57BLLiverCarbon TetrachlorideDisease Models, AnimalDiethylnitrosamineCell Transdifferentiation

Stichwörter der Autor:innen

hepatic stellate cellshepatocyteslineage tracingliver fibrosis and cirrhosistrans‐differentiation

Substanzen

Transforming Growth Factor betaBenzamidesChir 990214-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideDioxolesPyridinesPyrimidinesGlycogen Synthase Kinase 3Carbon TetrachlorideDiethylnitrosamine

Autor:innen und Institutionen

  • Institute of Metabolism & Integrative Biology, Fudan University, Shanghai, China.
  • National Center for Liver Cancer, Shanghai, China.
  • Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.
  • International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Naval Medical University, Shanghai, China.
  • Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.

ORCID-Profile: Han Wang

Förderung

  • Natural Science Foundation of Shanghai Municipality
  • National Natural Science Foundation of China
  • National Science and Technology Major Project

Zitieren

APA

Zhu, X. J., Zhong, Z., Du, J. C., Zhang, J. Y., Zhang, X., Cui, X. L., Guan, L. T., Hu, Y. Y., Chen, C., Wang, H., Wu, X. Y., Zhang, W. J., Zhang, P. L., & Wang, H. Y. (2025). Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co‐Inhibition of TGF ‐β and GSK ‐3 Signalling. Liver International. https://doi.org/10.1111/liv.70187

Vancouver

Zhu XJ, Zhong Z, Du JC, Zhang JY, Zhang X, Cui XL, et al. Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co‐Inhibition of TGF ‐β and GSK ‐3 Signalling. Liver International. 2025. doi:10.1111/liv.70187

BibTeX
@article{Zhu2025,
  author = {Zhu, Xiang-Jie and Zhong, Zhi and Du, Jiang-Chuan and Zhang, Jiu-Yu and Zhang, Xu and Cui, Xiu-Liang and Guan, Ling-Ting and Hu, Yan-Yu and Chen, Can and Wang, Han and Wu, Xiang-Yu and Zhang, Wei-Jia and Zhang, Pei-Lin and Wang, Hong-Yang},
  title = {Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co‐Inhibition of TGF ‐β and GSK ‐3 Signalling},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70187}
}
Kostenlos starten →